Last reviewed · How we verify

IMA970A plus CV8102 and Cyclophosphamide — Competitive Intelligence Brief

IMA970A plus CV8102 and Cyclophosphamide (IMA970A plus CV8102 and Cyclophosphamide) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline.

phase 1 Small molecule Live · refreshed every 30 min

Target snapshot

IMA970A plus CV8102 and Cyclophosphamide (IMA970A plus CV8102 and Cyclophosphamide) — National Cancer Institute, Naples.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
IMA970A plus CV8102 and Cyclophosphamide TARGET IMA970A plus CV8102 and Cyclophosphamide National Cancer Institute, Naples phase 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape

No sponsor landscape data.

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). IMA970A plus CV8102 and Cyclophosphamide — Competitive Intelligence Brief. https://druglandscape.com/ci/ima970a-plus-cv8102-and-cyclophosphamide. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators: